Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011;33(3):202-6.
doi: 10.5581/1516-8484.20110054.

The expression of CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia

Ana Paula Alegretti  1 , Christina Matzenbacher Bittar, Rosane Bittencourt, Amanda Kirchner Piccoli, Laiana Schneider, Lúcia Mariano Silla, Suzane Dal Bó, Ricardo Machado Xavier
Affiliations

The expression of CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia

Ana Paula Alegretti et al. Rev Bras Hematol Hemoter. 2011.

Abstract

Background: The expression of CD56 is considered a bad prognostic factor for overall survival, lower rates or short complete remission and extramedullary invasion but the results are controversial. The importance of validating new prognostic parameters in acute leukemias was the reason to investigate the CD56 expression in blast cells of patients with acute myeloid leukemia.

Methods: A cohort of 48 patients treated at Hospital de Clinicas de Porto Alegre and diagnosed with acute myeloid leukemia as classified by the French-American-British group (FAB) criteria using cell morphology, cytochemistry and flow cytometry were evaluated.

Results: Eight cases (16.7%) were CD56 positive without correlation to age or gender. The highest incidence of CD56 positivity was in FAB subtypes M4 and M5. The death rate during induction was not significantly different between patients with and without CD56 expression (62.5% vs. 27.5%; p-value = 0.097). However, patients that expressed CD56 had significantly lower overall survival than those who did not (mean 4.0 months vs. 14.5 months; p-value = 0.03).

Conclusions: The data suggest that expression of CD56 in acute myeloid leukemia may be indicative of poor prognosis because it is associated with a shorter overall survival. The death rate during induction was not significantly different despite an apparent difference in proportions between groups.

Keywords: Antigens, CD56; Leukemia, Myeloid; Prognosis.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interest

Figures

Figure 1
Figure 1
Overall survival estimated using the Kaplan-Meier method in CD56+ (n = 8) and CD56- (n = 39) acute myeloid leukemia patients
See this image and copyright information in PMC

Comment in

  • The expression of the CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia. :177–177. doi: 10.5581/1516-8484.20110048

References

    1. Smith M, Barnett M, Bassan R, Gatta G, Tondini C, Kern W.Adult acute myeloid leukaemia. Crit Rev Oncol Hematol. 2004; 50(3): 197-222 - PubMed
    1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985; 103(4): 620-5 - PubMed
    1. Wood BL.Myeloid malignancies: myelodysplastic syndromes, myeloproliferative disorders, and acute myeloid leukemia. Clin Lab Med. 2007; 27(3): 551-75, vii. - PubMed
    1. Stewart CC.Clinical applications of flow cytometry. Immunologic methods for measuring cell membrane and cytoplasmic antigens. Cancer. 1992; 69(6Suppl): 1543-52 - PubMed
    1. Ball ED, Davis RB, Griffin JD, Mayer RJ, Davey FR, Arthur DC, et al. Prognostic value of lymphocyte surface markers in acute myeloid leukemia. Blood. 1991; 77(10): 2242-50 - PubMed

LinkOut - more resources